Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$16.47 USD
+0.81 (5.17%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $16.45 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.47 USD
+0.81 (5.17%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $16.45 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -4.17% and 29.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 0.70% and 30.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
by Zacks Equity Research
Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies are part of the Zacks Screen of the Week article.
3 Top Breakout Stocks Worth a Buy for Attractive Returns
by Tirthankar Chakraborty
Phathom Pharmaceuticals (PHAT), Universal Stainless & Alloy Products (USAP) and Arlo Technologies (ARLO) are the breakout picks for today.
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Phathom Pharmaceuticals, Inc. (PHAT) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.
Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy
by Zacks Equity Research
Phathom Pharmaceuticals, Inc. (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax
by Zacks Equity Research
Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
by Zacks Equity Research
Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
by Zacks Equity Research
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
Phathom Pharmaceuticals (PHAT) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.